Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5195741
Max Phase: Preclinical
Molecular Formula: C48H50N12O7
Molecular Weight: 907.00
Associated Items:
ID: ALA5195741
Max Phase: Preclinical
Molecular Formula: C48H50N12O7
Molecular Weight: 907.00
Associated Items:
Canonical SMILES: CN(CCCNC(=O)CNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)C(C)(C)C=C(C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
Standard InChI: InChI=1S/C48H50N12O7/c1-48(2,57(3)22-9-21-51-38(62)26-52-35-14-7-13-34-39(35)47(66)59(46(34)65)36-19-20-37(61)55-44(36)63)24-30(25-49)45(64)58-23-8-10-31(27-58)60-43-40(42(50)53-28-54-43)41(56-60)29-15-17-33(18-16-29)67-32-11-5-4-6-12-32/h4-7,11-18,24,28,31,36,52H,8-10,19-23,26-27H2,1-3H3,(H,51,62)(H2,50,53,54)(H,55,61,63)/t31-,36?/m1/s1
Standard InChI Key: TXZDWTVEZQSZKM-RACIXVTASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 907.00 | Molecular Weight (Monoisotopic): 906.3925 | AlogP: 4.21 | #Rotatable Bonds: 15 |
Polar Surface Area: 250.87 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 19 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.58 | CX Basic pKa: 8.21 | CX LogP: 2.88 | CX LogD: 2.00 |
Aromatic Rings: 5 | Heavy Atoms: 67 | QED Weighted: 0.05 | Np Likeness Score: -0.93 |
1. Zhong Y, Chi F, Wu H, Liu Y, Xie Z, Huang W, Shi W, Qian H.. (2022) Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond., 231 [PMID:35092900] [10.1016/j.ejmech.2022.114142] |
Source(1):